

Journal Meeting

Defibrillator charging before rhythm analysis significantly reduces hands-off time during resuscitation: a simulation study.

American Journal of Emergency Medicine (2013) 31, 395–400
Lars Koch Hansen MD^{a,*}, Lars Folkestad MD^b, Mikkel Brabrand MD^c

報告者：PGY莊梓昱 指導者：李尚醫師
2013.3.12

Introduction

- Two pivotal importance of treating a patient in cardiac arrest.
 - High-Quality Chest compression
 - Rapid defibrillation
- Studies have shown that **ANY INCREASE in hands-off time** leads to significantly increased mortality.

Yu T et al. Adverse outcomes of interrupted precordial compression during automated defibrillation. Circulation 2002;106:368-72



Guideline told us ...

- 2010 International guidelines for resuscitation suggest interruptions in chest compression should be less than 5 sec. → **It's Hard !!!**

Koster RW et al. Part 5: adult basic life support: 2010 international consensus on cardiopulmonary resuscitation and emergency cardiovascular care science with treatment recommendations. Resuscitation 2010;81(Suppl. 1):e48-70

- 2005 European Resuscitation Council (ERC) guideline:
 - ALS provider keep **hands off while charging defibrillator.**
- 2010 ERC guideline :
 - Keep hands off while rhythm check, keep **compression while charging defibrillator**, and remove for shock delivery.

Author's hypothesis

- Hands-off time in the context of defibrillation can be reduced even further with simple means.
- This study using an alternative sequence for defibrillation of cardiac arrests could be reduced compared to both 2005 and 2010 ALS guideline.

Methods

- Equipment : Resusci Anne HLR-D mannequin and Lifepak 12 and 20 defibrillators.
 - unable to record data on the quality of chest compression.
- Participants
 - On call junior physicians at regional Danish hospital
 - All volunteers.




Experiment

- Participant randomly assigned to preplanned scenarios by a 6-sided dice roll.
- All were confronted with both pulseless VT and asystole.
- Each experiment lasted until the participants had treated both pVT and asystole using either 2005 or 2010 guideline or alternative sequence according to randomization.

Experiment

- Participant was set to be team leader and handle defibrillation.
- Start and stop of chest compressions and ventilation were handled on the order of team leader, and the stand-ins had no decisions.
- Screen was cover until the order to halt the chest compression by team leader.
- Hands-off time was recorded using a manual timer.



Information about participants

Table Demographics/information about participants


Participant specialty	Level of training	No. of CPRs	Years since graduation
ERC 2005 vs alternative sequence:			
1 Medicine	Residency	25	4
2 Medicine	Intership	2	0
3 Medicine	Residency	6	7
4 Medicine	Residency	12	2
5 Medicine	Intership	8	0
6 Medicine	Residency	15	5
7 Medicine	Residency	11	4
8 Medicine	Intership	1	0
9 Anaesthesia	Specialist	25	12
10 Cardiology	Residency	10	5

ERC 2010 vs alternative sequence

1 Medicine	Residency	2	2
2 Cardiology	Specialist	100	24
3 Medicine	Residency	10	16
4 Medicine	Residency	20	1
5 Medicine	Intership	0	0
6 Medicine	Residency	1	2
7 Medicine	Intership	3	0
8 Medicine	Residency	20	3
9 Medicine	Intership	0	0
10 Medicine	Residency	20	3
11 Medicine	Residency	50	1
12 Medicine	Residency	25	1


Results

- 2005 ERC guideline
 - overall mean hands-off time : 13.0 sec
 - alternative sequence : 6.7 sec
 - 2010 ERC guideline
 - overall mean hands-off time: 5.6 sec
 - alternative sequence : 3.9 sec
- $P < 0.01$
- $P < 0.01$




If we look at pVT only...

- 2010 ERC guideline
 - overall mean hands-off time : 7.6 sec
 - Alternative sequence : 4.5 sec
- $P < 0.01$



No significant difference in asystole



Discussions

- Only a small alteration could make a big change, we were able to reach hands-off time < 5 sec.
- Study showed even a brief pause in chest compression → perfusion pressure of the coronary and carotid arteries fell extremely.
- Our alternative sequence compared to
 - 2005 ERC : 6.3 sec reduction
 - 2010 ERC : 1.7 sec reduction

Data from defibrillators showed us

- Most of the time, chest compression are often not resumed while charging.
- Rescuers often thought (1) unnecessary to resume chest compression for such a brief interval (2) **afraid of being shocked accidentally**.
 - Major objection to the alternative sequence.

Potential increased risk of shocking ALS providers ?

- Limited experienced junior physicians with only brief introduction to alternative sequence.
 - However, 88 rhythm checks in our study show no examples of potential dangerous defibrillations.
- Edelson et al analyzed 562 defibrillations only 1 shock was delivered while chest compression was ongoing.
 - compression still continued at same rate, suggesting no harm was done.
- Recent studies indicates that chest compression can safely be continued during defibrillations.

Paddle v.s. Pads

- Only when using pads and alternative sequence, we were able to have hands-off time <5 sec. (3.9sec)
- In the updated 2010, use of pads is encouraged, and it came close to 5 sec. (5.6 sec)
- And our alternative sequence have only 1 intermission compared to 2010 with 2 intermissions.



Limitations

- A simulation study
 - participants may be less cautious
 - no normal chaos, noise, confusion
- Only focus on defibrillation itself
 - not a full-scale simulation
- Old Anne
 - unable to record the quality of chest compression and ventilation (limited findings)

Limitations

- Manual timer
 - inferior method compared to automatic registration by novel resuscitation Anne.
 - potential measurement error in all sequences.
- We measured the interval from the participants **asked** for chest compression to be halted until they were **asked** to resume.
 - potentially lead to significant effect of individual participants.

Take home message

- Charging of the defibrillator before rhythm analysis significantly reduced hands-off time compared with ERC 2005 and ERC 2010 guidelines.
- Pads is recommended for current defibrillation strategy.
- It's not that risky to have chest compression while defibrillation.

Journal Meeting

Red cell distribution width as a prognostic marker in patients with community-acquired pneumonia.

American Journal of Emergency Medicine (2013) 31, 72–79
Jae Hyuk Lee MD, PhD, Hea Jin Chung MD, Kyuseok Kim MD, PhD*,
You Hwan Jo MD, PhD, Joong Eui Rhee MD, PhD, Yu Jin Kim MD, PhD,
Kyeong Won Kang MD

報告者 : PGY莊梓昱 指導者 : 李尚醫師
2013.3.12

Introduction

- Community-acquired pneumonia (CAP)
 - leading infectious cause of death
 - prognostication is important with management.
- Current prognostic scales
 - Pneumonia Severity Index (PSI)
Age, gender, comorbid disease, PE, Lab
 - CURB-65
Confusion, Urea, RR, BP, Age ≥ 65

Prognostic scales

- These scales are used to **predict** probability of mortality/morbidity among 30-day survival.
- **PSI**
 - Useful for identifying low-risk patient.
 - Could be safely managed as outpatient.
- **CURB-65**
 - Useful for identifying high-risk patient.
 - risk of death.
- Thus, we need add some more biomarkers to improve the prognostic performance.

Red cell distribution width

- RDW - a coefficient of variation of circulating red cells.
 - reflect the heterogeneity of red cell volume
 - a component of CBC
 - limited to differential diagnosis of anemia
- Recently, reports associated **elevated RDW** with outcomes in :
 - > Cardiovascular disease ; Rheumatoid arthritis
 - > Colon cancer ; Metabolic syndrome
- We hypothesized that RDW would be associated with 30-day mortality and prognosis factor with CAP.



Methods

- **Study design**
 - Retrospective analysis of a prospective registry database
 - 950-bed tertiary academic hospital
 - Annual ED census of 67,000
- **Participants**
 - visit ED, and hospitalized for CAP by attending physician of ED based on PSI scale and other medical conditions.
 - between April 2008 and March 2011.
 - All are older than 18yr

Methods - Selection of participants

- CAP was defined as pulmonary infiltrate on CXR, and symptoms consistent with pneumonia, which were not acquired in hospital or nursing home.
- Also, CXR (X) initial, abnormal lung sound, f/u CXR (O).
- Exclusion criterias
 - transfer, discharge from hospital within 10days, experience pneumonia within past 30days.
 - active TB, HIV(+),
 - chronic immunosuppressed (organ transplant, post-splenectomy, >10mg/d prednisolone < 30 day, neutropenia)

Methods - Data collection

- **Initial lab data at ED**
 - leukocyte count, Hb, Hct, MCV, MCH, RDW, plt
 - Glu, crea, BUN, albumin, T-cho, PT, aPTT, CRP.
 - PSI and CURB-65 while ED visit.
- Determine the status of patient 1 month after initial ED visit, ascertain death by medical record or by telephone after discharge.
 - 744 pt hospitalized, 702 pt identified by chart.
 - 42 pt telephone contact, 10 pt were transferred to other facility after acute management for CAP.

Methods - Outcome measure

- **Primary end point**
 - 30 day mortality after the ED visit.
 - survival time was also investigated.
- **Secondary end point**
 - hospital length of stay
 - use of vasopressors
 - ICU admission
 - mechanical ventilator require

Methods – Primary data analysis

- Impact of RDW on outcome of CAP patients
 - categorized into quartiles

RDW	<13.3%	13.3–14.1%	14.1–15.2%	>15.2%
-----	--------	------------	------------	--------

- Test of the added ability of RDW to predict 30-day mortality.

Results – Characteristics

Table 1 Patient characteristics by quartiles of RDW

Variables	Total patients n = 744	Quartile (RDW)				P
		<13.3 (n = 196)	13.3-14.1 (n = 172)	14.1-15.2 (n = 190)	≥ 15.2 (n = 186)	
Age (mean ± SD)	70.1 ± 15.0	65.2 ± 17.5	70.6 ± 14.3	73.1 ± 13.8	71.5 ± 12.7	<.001
Male sex (%)	238 (32.0)	62 (33.2)	65 (37.8)	58 (30.5)	50 (26.9)	.159
Comorbidities, n (%)						
Heart failure	18 (2.4)	2 (1.0)	2 (1.2)	8 (4.2)	6 (3.2)	.120
Renal failure	83 (11.2)	16 (8.2)	15 (8.7)	24 (12.6)	28 (15.1)	.113
Liver disease	44 (5.9)	7 (3.6)	11 (6.4)	15 (7.9)	11 (5.9)	.322
COPD	148 (19.9)	38 (19.4)	39 (22.7)	38 (20.0)	33 (17.7)	.704
Neoplasm	195 (26.2)	35 (17.9)	26 (15.1)	55 (29.0)	79 (42.5)	<.001
Neurologic disease	187 (25.1)	42 (21.4)	44 (25.6)	56 (29.5)	45 (24.2)	.331
Diabetes mellitus	222 (29.8)	48 (24.5)	50 (29.1)	63 (33.2)	61 (32.8)	.207

- Overall 30-day mortality :13.4%

Table 1 Patient characteristics by quartiles of RDW

Variables	Total patients n = 744	Quartile (RDW)				P
		<13.3 (n = 196)	13.3-14.1 (n = 172)	14.1-15.2 (n = 190)	≥ 15.2 (n = 186)	
Laboratory findings						
WBC	12.7 ± 6.8	13.0 ± 5.8	13.2 ± 7.1	12.8 ± 5.9	11.7 ± 8.1	.138
Hemoglobin level	121.1 ± 22.2	123.0 ± 18.8	122.5 ± 20.0	122.3 ± 20.0	110.8 ± 23.8	<.001
Hematocrit (%)	36.1 ± 6.4	38.0 ± 5.2	36.8 ± 6.1	36.8 ± 6.0	32.8 ± 6.7	<.001
MCV	93.4 ± 6.7	93.8 ± 4.7	93.0 ± 5.3	94.1 ± 6.4	92.5 ± 9.3	.061
MCH	31.3 ± 2.6	32.0 ± 1.9	31.4 ± 2.1	31.5 ± 2.3	30.5 ± 3.6	<.001
Platelet (× 10 ³ /mm ³)	252.8 ± 127.0	252.1 ± 110.5	257.4 ± 110.4	256.4 ± 153.2	245.7 ± 128.8	.811
Glucose (mg/dL)	164.6 ± 111.6	160.0 ± 80.7	178.6 ± 144.3	164.7 ± 123.0	156.3 ± 90.3	.252
Albumin (g/dL)	3.4 ± 0.6	3.7 ± 0.5	3.5 ± 0.6	3.4 ± 0.5	3.2 ± 0.6	<.001
Cholesterol (g/dL)	143.0 ± 40.3	146.5 ± 34.9	144.6 ± 40.4	148.4 ± 42.6	132.3 ± 41.4	<.001
BUN (mg/dL)	24.4 ± 16.9	19.5 ± 11.6	22.8 ± 16.2	26.3 ± 18.2	29.0 ± 19.3	<.001
Creatinine (mg/dL)	1.4 ± 1.3	1.2 ± 1.0	1.3 ± 1.2	1.5 ± 1.5	1.6 ± 1.5	.052
Arterial pH	7.43 ± 0.07	7.44 ± 0.07	7.42 ± 0.07	7.42 ± 0.07	7.43 ± 0.09	.392
Pao ₂	68.6 ± 29.7	69.3 ± 25.1	67.2 ± 25.3	68.7 ± 35.8	69.1 ± 31.1	.921
Paco ₂	35.2 ± 10.9	35.1 ± 9.3	36.2 ± 12.0	35.7 ± 10.8	34.0 ± 11.2	.320
HCO ₃ ⁻	22.6 ± 5.1	23.0 ± 3.7	22.8 ± 5.4	22.8 ± 5.6	21.8 ± 5.3	.104
Na	134.7 ± 7.6	134.7 ± 9.8	134.1 ± 6.1	135.0 ± 6.6	135.1 ± 7.0	.627
K	4.2 ± 0.7	4.1 ± 0.5	4.2 ± 0.7	4.2 ± 0.7	4.3 ± 0.7	.059
Cl	99.6 ± 6.7	99.9 ± 5.3	98.5 ± 7.0	99.6 ± 7.0	100.3 ± 7.4	.082
PT (INR)	1.2 ± 0.4	1.14 ± 0.30	1.19 ± 0.47	1.21 ± 0.28	1.27 ± 0.37	.004
apt (s)	43.2 ± 11.9	44.5 ± 13.6	42.1 ± 13.2	41.9 ± 8.0	44.3 ± 12.2	.060
CRP (mg/dL)	13.5 ± 9.4	12.9 ± 8.4	14.3 ± 10.2	13.2 ± 10.1	13.7 ± 8.9	.524
PSI score						
I, II	132 (17.7)	66 (50.0)	35 (26.5)	15 (11.4)	16 (12.1)	<.001
III	136 (18.3)	50 (36.8)	40 (29.4)	31 (22.8)	15 (11.0)	
IV	300 (40.3)	61 (20.3)	68 (22.7)	82 (27.3)	89 (29.7)	
V	176 (23.7)	19 (10.8)	29 (16.5)	62 (35.2)	66 (37.5)	
CURB-65						
0	96 (12.9)	47 (49.0)	22 (22.9)	13 (13.5)	14 (14.6)	
1	214 (28.8)	71 (33.2)	58 (27.1)	52 (24.3)	33 (15.4)	
2	253 (34.0)	48 (19.9)	55 (21.7)	71 (28.1)	79 (31.2)	
3	133 (17.9)	25 (18.8)	30 (22.6)	42 (31.6)	36 (27.1)	
4	38 (5.1)	4 (10.5)	5 (13.2)	10 (26.3)	19 (50.0)	
5	10 (1.3)	1 (10.0)	2 (20.0)	2 (20.0)	5 (50.0)	

Results

- Independent risk factors associated with 30-day mortality.

Table 2 Multivariate logistic regression analysis


Variables	Odds ratio (95% CI)	P
RDW < 13.3	Reference	
RDW 13.3-14.1	0.73 (0.28-1.91)	.518
RDW 14.1-15.2	1.11 (0.47-2.62)	.815
RDW ≥ 15.2	2.37 (1.04-5.42)	.040
PSI class I, II	Reference	
PSI class III	1.47 (0.24-8.93)	.678
PSI class IV	4.76 (1.01-22.53)	.049
PSI class V	7.10 (1.42-35.42)	.017
CURB-65		
0	Reference	
1	1.34 (0.25-7.20)	.730
2	2.26 (0.45-11.30)	.323
3	2.44 (0.46-12.82)	.292
4	3.42 (0.58-20.06)	.174
5	37.02 (2.49-550.32)	.009
Hematocrit	1.03 (0.99-1.07)	.191
MCH	1.01 (0.92-1.10)	.869
Albumin	0.19 (0.11-0.33)	<.001
Cholesterol	1.01 (1.00-1.01)	.073
Prothrombin time	1.14 (0.57-2.26)	.716

Results- effect of each quartile of RDW

Table 3 Community-acquired pneumonia outcomes stratified by RDW

Variables	Total patients (n = 744)	Quartile 1 (RDW < 13.3, n = 196)	Quartile 2 (13.3 ≤ RDW < 14.1, n = 172)	Quartile 3 (14.1 ≤ RDW < 15.2, n = 190)	Quartile 4 (RDW ≥ 15.2, n = 186)	P
30-d mortality, n (%)	100 (13.4)	11 (5.6)	12 (7.0)	24 (12.6)	53 (28.5)	<.001
PSI						
I, II	2/132 (1.5%)	0/66 (0.0%)	0/35 (0.0%)	0/15 (0.0%)	2/16 (12.5%)	.026
III	4/136 (2.9%)	1/50 (2.0%)	1/40 (2.5%)	1/31 (3.2%)	1/15 (6.7%)	.730
IV	41/300 (13.7)	6/61 (9.8%)	4/68 (5.9%)	10/82 (12.2%)	21/89 (23.6%)	.011
V	53/176 (30.1)	4/19 (21.1%)	7/29 (24.1%)	13/62 (21.0%)	29/66 (43.9%)	.026
CURB-65						
0	2/96 (2.1%)	1/47 (2.1%)	0/22 (0.0%)	1/13 (7.7%)	0/14 (0.0%)	.392
1	11/214 (5.1%)	0/71 (0.0%)	3/58 (5.2%)	3/52 (5.8%)	5/33 (15.2%)	.006
2	36/253 (14.2%)	4/48 (8.3%)	2/55 (3.6%)	7/71 (9.9%)	23/79 (29.1%)	<.001
3	27/133 (20.3%)	4/25 (16.0%)	3/30 (10.0%)	10/42 (23.8%)	10/36 (27.8%)	.282
4	16/38 (42.1%)	1/4 (25.0%)	2/5 (40.0%)	2/10 (20.0%)	11/19 (57.9%)	.237
5	8/10 (80%)	1/1 (100.0%)	2/2 (100.0%)	1/2 (50.0%)	4/5 (80.0%)	1.000
Secondary outcomes						
HLOS, median (IQR)	11 (7-18)	10 (6-15)	11 (8-17.5)	11.5 (8-21)	12 (8-20)	.004
ICU admission, n (%)	107 (14.4)	18 (9.2)	28 (16.3)	29 (15.3)	32 (17.2)	.075
Vasopressor use, n (%)	103 (13.8)	10 (5.1)	23 (13.4)	32 (16.8)	38 (20.4)	<.001
MV use, n (%)	102 (13.7)	17 (8.7)	25 (14.5)	28 (14.7)	32 (17.2)	.080

Results – survival curve of quartile RDW



Results – Cox proportional hazard regression analysis


- Evaluate the relation between RDW and outcomes while adjusting for age, sex, PSI and other risk factors.

Table 4 Hazard ratios by categories of RDW

Model	Hazard ratio (95% CI)				Test for trend P value
	RDW quartile 1	RDW quartile 2	RDW quartile 3	RDW quartile 4	
Model 1	1.0 (reference)	0.86 (0.36-2.05)	1.28 (0.59-2.74)	2.31 (1.12-4.79)	<.001
Model 2	1.0 (reference)	0.76 (0.32-1.81)	1.06 (0.49-2.28)	2.06 (1.01-4.20)	<.001
Model 3	1.0 (reference)	0.88 (0.37-2.08)	1.37 (0.64-2.95)	2.45 (1.20-4.98)	<.001

Model 1 is adjusted for age, sex, neoplastic disease, hematocrit, albumin, cholesterol, BUN, and prothrombin time. Model 2 is adjusted for PSI, albumin, cholesterol, and prothrombin time. Model 3 is adjusted for CURB-65, albumin, cholesterol, and prothrombin time.

Results – Add RDW to current scales



Limitations

- Single institution and only included patient hospitalized via the ED.
- No gather data about anemia, transfusion status, or nutritional deficiency.
- ED physician knew the results of the lab values, including RDW, before enrollment.

Discussions

- This study demonstrate higher RDW associated with increased 30-day mortality in CAP patient, especially in RDW >15.2%.
- Length of hospital stay and vasopressor require were also affected by RDW ↑ .
- Exact mechanism ?

Currently we knew ...

- Suggest “inflammation” and “oxidative stress” affect red cell homeostasis.
- Studies showed RDW have a strong association with inflammatory biomarkers in general outpatient.
- Serum antioxidant level (selenium, carotenoids) have association with RDW in older women.
- However, CRP level were not different across the quartile change of RDW → CRP-insensitive inflammatory mechanism

Role of albumin

- Among other variables, albumin was significant correlated with RDW, and was identify as an independent predictor of mortality in multi-analysis.
- Thus, low serum albumin level in high RDW patient may reflect the severity of CAP.
- In Future, while revise for the severity scale, may consider adding these biomarkers.

Thank you for your listening !